Yahoo
XETRA - Delayed Quote EUR

Biofrontera AG (B8FK.DE)

2.9300 -0.1200 (-3.93%)
At close: October 30 at 5:35:30 PM GMT+1
Chart Range Bar
Loading chart for B8FK.DE
  • Previous Close 3.0500
  • Open 2.9400
  • Bid 2.9400 x --
  • Ask 3.1400 x --
  • Day's Range 2.9300 - 3.0400
  • 52 Week Range 2.2100 - 5.1000
  • Volume 55
  • Avg. Volume 1,531
  • Market Cap (intraday) 17.805M
  • Beta (5Y Monthly) -0.41
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2800
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. In addition, the company focus on photodynamic therapy (PDT) for the treatment of actinic keratosis and keratinocyte skin cancers, including basal cell carcinoma. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

www.biofrontera.com

54

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

B8FK.DE
20.08%
DAX P (^GDAXI)
5.42%

1-Year Return

B8FK.DE
9.74%
DAX P (^GDAXI)
7.05%

3-Year Return

B8FK.DE
74.63%
DAX P (^GDAXI)
75.44%

5-Year Return

B8FK.DE
93.74%
DAX P (^GDAXI)
64.56%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY22
Revenue 8.51M
Earnings -8.64M
Profit Margin -101.59%

Q3

FY21

Q4

FY21

Q1

FY22

Q2

FY22

-20M
0
20M
40M
-400.0%
-200.0%
0.0%
200.0%
400.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    32.95%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    15.96M

  • Net Income Avi to Common (ttm)

    990k

  • Diluted EPS (ttm)

    -0.2800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.11M

  • Total Debt/Equity (mrq)

    8.00%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More
Mobilize your Website
View Site in Mobile | Classic
Share by: